Survival benefit with kidney transplants from HLA-incompatible live donors

B. J. Orandi, X. Luo, A. B. Massie, J. M. Garonzik-Wang, B. E. Lonze, R. Ahmed, K. J. Van Arendonk, Mark D Stegall, S. C. Jordan, J. Oberholzer, T. B. Dunn, L. E. Ratner, S. Kapur, R. P. Pelletier, J. P. Roberts, M. L. Melcher, P. Singh, D. L. Sudan, M. P. Posner, J. M. El-AmmR. Shapiro, M. Cooper, G. S. Lipkowitz, M. A. Rees, C. L. Marsh, B. R. Sankari, D. A. Gerber, P. W. Nelson, J. Wellen, A. Bozorgzadeh, A. O. Gaber, R. A. Montgomery, D. L. Segev

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

BACKGROUND A report from a high-volume single center indicated a survival benefit of receiving a kidney transplant from an HLA-incompatible live donor as compared with remaining on the waiting list, whether or not a kidney from a deceased donor was received. The generalizability of that finding is unclear. METHODS In a 22-center study, we estimated the survival benefit for 1025 recipients of kidney transplants from HLA-incompatible live donors who were matched with controls who remained on the waiting list or received a transplant from a deceased donor (waitinglist-or-Transplant control group) and controls who remained on the waiting list but did not receive a transplant (waiting-list-only control group). We analyzed the data with and without patients from the highest-volume center in the study. RESULTS Recipients of kidney transplants from incompatible live donors had a higher survival rate than either control group at 1 year (95.0%, vs. 94.0% for the waiting-list-ortransplant control group and 89.6% for the waiting-list-only control group), 3 years (91.7% vs. 83.6% and 72.7%, respectively), 5 years (86.0% vs. 74.4% and 59.2%), and 8 years (76.5% vs. 62.9% and 43.9%) (P

Original languageEnglish (US)
Pages (from-to)940-950
Number of pages11
JournalNew England Journal of Medicine
Volume374
Issue number10
DOIs
StatePublished - Mar 10 2016

Fingerprint

Waiting Lists
Tissue Donors
Transplants
Kidney
Survival
Control Groups
Survival Rate

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Orandi, B. J., Luo, X., Massie, A. B., Garonzik-Wang, J. M., Lonze, B. E., Ahmed, R., ... Segev, D. L. (2016). Survival benefit with kidney transplants from HLA-incompatible live donors. New England Journal of Medicine, 374(10), 940-950. https://doi.org/10.1056/NEJMoa1508380

Survival benefit with kidney transplants from HLA-incompatible live donors. / Orandi, B. J.; Luo, X.; Massie, A. B.; Garonzik-Wang, J. M.; Lonze, B. E.; Ahmed, R.; Van Arendonk, K. J.; Stegall, Mark D; Jordan, S. C.; Oberholzer, J.; Dunn, T. B.; Ratner, L. E.; Kapur, S.; Pelletier, R. P.; Roberts, J. P.; Melcher, M. L.; Singh, P.; Sudan, D. L.; Posner, M. P.; El-Amm, J. M.; Shapiro, R.; Cooper, M.; Lipkowitz, G. S.; Rees, M. A.; Marsh, C. L.; Sankari, B. R.; Gerber, D. A.; Nelson, P. W.; Wellen, J.; Bozorgzadeh, A.; Gaber, A. O.; Montgomery, R. A.; Segev, D. L.

In: New England Journal of Medicine, Vol. 374, No. 10, 10.03.2016, p. 940-950.

Research output: Contribution to journalArticle

Orandi, BJ, Luo, X, Massie, AB, Garonzik-Wang, JM, Lonze, BE, Ahmed, R, Van Arendonk, KJ, Stegall, MD, Jordan, SC, Oberholzer, J, Dunn, TB, Ratner, LE, Kapur, S, Pelletier, RP, Roberts, JP, Melcher, ML, Singh, P, Sudan, DL, Posner, MP, El-Amm, JM, Shapiro, R, Cooper, M, Lipkowitz, GS, Rees, MA, Marsh, CL, Sankari, BR, Gerber, DA, Nelson, PW, Wellen, J, Bozorgzadeh, A, Gaber, AO, Montgomery, RA & Segev, DL 2016, 'Survival benefit with kidney transplants from HLA-incompatible live donors', New England Journal of Medicine, vol. 374, no. 10, pp. 940-950. https://doi.org/10.1056/NEJMoa1508380
Orandi BJ, Luo X, Massie AB, Garonzik-Wang JM, Lonze BE, Ahmed R et al. Survival benefit with kidney transplants from HLA-incompatible live donors. New England Journal of Medicine. 2016 Mar 10;374(10):940-950. https://doi.org/10.1056/NEJMoa1508380
Orandi, B. J. ; Luo, X. ; Massie, A. B. ; Garonzik-Wang, J. M. ; Lonze, B. E. ; Ahmed, R. ; Van Arendonk, K. J. ; Stegall, Mark D ; Jordan, S. C. ; Oberholzer, J. ; Dunn, T. B. ; Ratner, L. E. ; Kapur, S. ; Pelletier, R. P. ; Roberts, J. P. ; Melcher, M. L. ; Singh, P. ; Sudan, D. L. ; Posner, M. P. ; El-Amm, J. M. ; Shapiro, R. ; Cooper, M. ; Lipkowitz, G. S. ; Rees, M. A. ; Marsh, C. L. ; Sankari, B. R. ; Gerber, D. A. ; Nelson, P. W. ; Wellen, J. ; Bozorgzadeh, A. ; Gaber, A. O. ; Montgomery, R. A. ; Segev, D. L. / Survival benefit with kidney transplants from HLA-incompatible live donors. In: New England Journal of Medicine. 2016 ; Vol. 374, No. 10. pp. 940-950.
@article{471f871b9c68495c967de4c8045b0129,
title = "Survival benefit with kidney transplants from HLA-incompatible live donors",
abstract = "BACKGROUND A report from a high-volume single center indicated a survival benefit of receiving a kidney transplant from an HLA-incompatible live donor as compared with remaining on the waiting list, whether or not a kidney from a deceased donor was received. The generalizability of that finding is unclear. METHODS In a 22-center study, we estimated the survival benefit for 1025 recipients of kidney transplants from HLA-incompatible live donors who were matched with controls who remained on the waiting list or received a transplant from a deceased donor (waitinglist-or-Transplant control group) and controls who remained on the waiting list but did not receive a transplant (waiting-list-only control group). We analyzed the data with and without patients from the highest-volume center in the study. RESULTS Recipients of kidney transplants from incompatible live donors had a higher survival rate than either control group at 1 year (95.0{\%}, vs. 94.0{\%} for the waiting-list-ortransplant control group and 89.6{\%} for the waiting-list-only control group), 3 years (91.7{\%} vs. 83.6{\%} and 72.7{\%}, respectively), 5 years (86.0{\%} vs. 74.4{\%} and 59.2{\%}), and 8 years (76.5{\%} vs. 62.9{\%} and 43.9{\%}) (P",
author = "Orandi, {B. J.} and X. Luo and Massie, {A. B.} and Garonzik-Wang, {J. M.} and Lonze, {B. E.} and R. Ahmed and {Van Arendonk}, {K. J.} and Stegall, {Mark D} and Jordan, {S. C.} and J. Oberholzer and Dunn, {T. B.} and Ratner, {L. E.} and S. Kapur and Pelletier, {R. P.} and Roberts, {J. P.} and Melcher, {M. L.} and P. Singh and Sudan, {D. L.} and Posner, {M. P.} and El-Amm, {J. M.} and R. Shapiro and M. Cooper and Lipkowitz, {G. S.} and Rees, {M. A.} and Marsh, {C. L.} and Sankari, {B. R.} and Gerber, {D. A.} and Nelson, {P. W.} and J. Wellen and A. Bozorgzadeh and Gaber, {A. O.} and Montgomery, {R. A.} and Segev, {D. L.}",
year = "2016",
month = "3",
day = "10",
doi = "10.1056/NEJMoa1508380",
language = "English (US)",
volume = "374",
pages = "940--950",
journal = "New England Journal of Medicine",
issn = "1533-4406",
publisher = "Massachussetts Medical Society",
number = "10",

}

TY - JOUR

T1 - Survival benefit with kidney transplants from HLA-incompatible live donors

AU - Orandi, B. J.

AU - Luo, X.

AU - Massie, A. B.

AU - Garonzik-Wang, J. M.

AU - Lonze, B. E.

AU - Ahmed, R.

AU - Van Arendonk, K. J.

AU - Stegall, Mark D

AU - Jordan, S. C.

AU - Oberholzer, J.

AU - Dunn, T. B.

AU - Ratner, L. E.

AU - Kapur, S.

AU - Pelletier, R. P.

AU - Roberts, J. P.

AU - Melcher, M. L.

AU - Singh, P.

AU - Sudan, D. L.

AU - Posner, M. P.

AU - El-Amm, J. M.

AU - Shapiro, R.

AU - Cooper, M.

AU - Lipkowitz, G. S.

AU - Rees, M. A.

AU - Marsh, C. L.

AU - Sankari, B. R.

AU - Gerber, D. A.

AU - Nelson, P. W.

AU - Wellen, J.

AU - Bozorgzadeh, A.

AU - Gaber, A. O.

AU - Montgomery, R. A.

AU - Segev, D. L.

PY - 2016/3/10

Y1 - 2016/3/10

N2 - BACKGROUND A report from a high-volume single center indicated a survival benefit of receiving a kidney transplant from an HLA-incompatible live donor as compared with remaining on the waiting list, whether or not a kidney from a deceased donor was received. The generalizability of that finding is unclear. METHODS In a 22-center study, we estimated the survival benefit for 1025 recipients of kidney transplants from HLA-incompatible live donors who were matched with controls who remained on the waiting list or received a transplant from a deceased donor (waitinglist-or-Transplant control group) and controls who remained on the waiting list but did not receive a transplant (waiting-list-only control group). We analyzed the data with and without patients from the highest-volume center in the study. RESULTS Recipients of kidney transplants from incompatible live donors had a higher survival rate than either control group at 1 year (95.0%, vs. 94.0% for the waiting-list-ortransplant control group and 89.6% for the waiting-list-only control group), 3 years (91.7% vs. 83.6% and 72.7%, respectively), 5 years (86.0% vs. 74.4% and 59.2%), and 8 years (76.5% vs. 62.9% and 43.9%) (P

AB - BACKGROUND A report from a high-volume single center indicated a survival benefit of receiving a kidney transplant from an HLA-incompatible live donor as compared with remaining on the waiting list, whether or not a kidney from a deceased donor was received. The generalizability of that finding is unclear. METHODS In a 22-center study, we estimated the survival benefit for 1025 recipients of kidney transplants from HLA-incompatible live donors who were matched with controls who remained on the waiting list or received a transplant from a deceased donor (waitinglist-or-Transplant control group) and controls who remained on the waiting list but did not receive a transplant (waiting-list-only control group). We analyzed the data with and without patients from the highest-volume center in the study. RESULTS Recipients of kidney transplants from incompatible live donors had a higher survival rate than either control group at 1 year (95.0%, vs. 94.0% for the waiting-list-ortransplant control group and 89.6% for the waiting-list-only control group), 3 years (91.7% vs. 83.6% and 72.7%, respectively), 5 years (86.0% vs. 74.4% and 59.2%), and 8 years (76.5% vs. 62.9% and 43.9%) (P

UR - http://www.scopus.com/inward/record.url?scp=84960466211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960466211&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa1508380

DO - 10.1056/NEJMoa1508380

M3 - Article

C2 - 26962729

AN - SCOPUS:84960466211

VL - 374

SP - 940

EP - 950

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 1533-4406

IS - 10

ER -